A Phase II, Patient- and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 (Siponimod) in Patients With Stroke Due to Intracerebral Hemorrhage (ICH)
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Siponimod (Primary) ; Siponimod (Primary)
- Indications Cerebral haemorrhage
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 30 Sep 2019 Planned number of patients changed from 100 to 60.
- 08 Mar 2019 Planned End Date changed from 17 Mar 2020 to 30 Nov 2020.
- 08 Mar 2019 Planned primary completion date changed from 17 Mar 2020 to 30 Nov 2020.